These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37795066)

  • 41. Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study.
    Devarajan TV; Venkataraman S; Kandasamy N; Oomman A; Boorugu HK; Karuppiah SKP; Balat D
    Indian J Endocrinol Metab; 2017; 21(5):745-750. PubMed ID: 28989886
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis.
    Ding Y; Liu Y; Qu Y; Lin M; Dong F; Li Y; Cao L; Lin S
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(8):2802-2817. PubMed ID: 35503625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
    Kumar S
    Indian J Endocrinol Metab; 2021; 25(4):326-331. PubMed ID: 35136740
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.
    Chatterjee S; Chatterjee S
    J Diabetes; 2014 May; 6(3):237-42. PubMed ID: 23879210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.
    Zang L; Han Y; Chen L; Hu D; Jin H; Yang N; Shi X; Liang L; Liu M; Fan H; Li Q; Mu Y
    Diabetes Ther; 2019 Aug; 10(4):1391-1405. PubMed ID: 31222594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study.
    Sakaue S; Kamigaki M; Yoshimura H; Nishimura M
    Curr Ther Res Clin Exp; 2008 Aug; 69(4):364-77. PubMed ID: 24692813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study.
    Balaji V
    Indian J Endocrinol Metab; 2013 Jul; 17(4):709-15. PubMed ID: 23961491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
    Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
    Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I; El Kafrawy N; Raouf R; Yousry D
    Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus.
    Panneerselvam P; Biswas D; Singh H; Dilip Kumar K; Ravi Kumar P; Kalra P; Revankar S; Warrier S
    Cureus; 2023 Oct; 15(10):e47190. PubMed ID: 38021574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
    Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.